Twist Bioscience (NASDAQ:TWST) Given New $54.00 Price Target at Robert W. Baird

Twist Bioscience (NASDAQ:TWST - Get Free Report) had its target price boosted by equities researchers at Robert W. Baird from $48.00 to $54.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Robert W. Baird's price target would indicate a potential upside of 3.25% from the stock's previous close.

A number of other brokerages have also issued reports on TWST. Scotiabank lifted their price target on Twist Bioscience from $50.00 to $54.00 and gave the stock a "sector outperform" rating in a research note on Tuesday, November 19th. TD Cowen reaffirmed a "buy" rating and set a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. Barclays dropped their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating for the company in a report on Tuesday, November 19th. Wolfe Research assumed coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an "outperform" rating and a $60.00 price target on the stock. Finally, Leerink Partners upped their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a research note on Thursday, October 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $53.80.

Twist Bioscience Stock Down 2.6 %

Shares of TWST stock traded down $1.40 during trading hours on Tuesday, hitting $52.30. 883,044 shares of the company's stock were exchanged, compared to its average volume of 796,482. Twist Bioscience has a fifty-two week low of $27.41 and a fifty-two week high of $60.90. The firm has a market cap of $3.12 billion, a P/E ratio of -14.53 and a beta of 1.87. The firm has a 50 day moving average of $48.84 and a two-hundred day moving average of $46.32.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. The company's revenue was up 24.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.75) earnings per share. On average, equities analysts forecast that Twist Bioscience will post -2.27 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Twist Bioscience news, insider Dennis Cho sold 806 shares of the company's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $39,776.10. Following the sale, the insider now owns 112,221 shares in the company, valued at $5,538,106.35. This represents a 0.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Robert Chess sold 3,600 shares of the business's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $47.26, for a total value of $170,136.00. Following the transaction, the director now directly owns 21,641 shares of the company's stock, valued at approximately $1,022,753.66. This represents a 14.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 59,002 shares of company stock valued at $2,851,681. 3.01% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Twist Bioscience

A number of hedge funds and other institutional investors have recently modified their holdings of TWST. ARK Investment Management LLC raised its stake in Twist Bioscience by 4.4% in the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company's stock valued at $260,040,000 after buying an additional 237,772 shares in the last quarter. State Street Corp raised its position in shares of Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company's stock worth $143,101,000 after acquiring an additional 526,028 shares in the last quarter. Geode Capital Management LLC lifted its stake in Twist Bioscience by 1.9% during the third quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company's stock worth $61,807,000 after purchasing an additional 26,145 shares during the last quarter. Thrivent Financial for Lutherans acquired a new position in Twist Bioscience in the third quarter valued at approximately $43,992,000. Finally, Wellington Management Group LLP increased its stake in Twist Bioscience by 188.5% in the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company's stock valued at $36,042,000 after purchasing an additional 521,272 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.